证券代码：603259 证券简称：药明康德 公告编号：临 2023-072 无锡药明康德新药开发股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2023 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2023 年第三季度报告》。为了便于广大投资者更全面深 入地了解本公司 2023 年第三季度业绩和经营情况，本公司拟于 2023 年 11 月 16 日（星期四）上午 10:00-11:00 召开业绩说明会，就投资者普遍关心的问题进行 交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2023 年第三 季度业绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普 遍关注的问题进行回答。 二、 业绩说明会召开的时间、地点 会议召开时间：2023 年 11 月 16 日（星期 ...

第三届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2023 年 11 月 2 日向本公司全体董事发出会议通知及会议材料，全体董事一致同 意豁免本次会议的通知期限要求，并以通讯表决方式于 2023 年 11 月 3 日召开第 三届董事会第五次会议。本次董事会会议应出席董事12人，实际出席董事12人。 会议由董事长 Ge Li（李革）召集。本次董事会符合《中华人民共和国公司法》 和《无锡药明康德新药开发股份有限公司章程》关于召开董事会会议的规定。 二、董事会会议审议情况 审议通过《关于与关联方签署框架协议暨日常关联交易的议案》 证券代码：603259 证券简称：药明康德 公告编号：临 2023-069 无锡药明康德新药开发股份有限公司 公司独立董事对本次关联交易已进行事前认可，同意提交董事会审议，并在 董事会审议时发表了同意的独立意见。 具体内容详见本公司同日于上海证券交易所网站（www.sse.com.cn） ...

《关于与关联方签署框架协议暨日常关联交易的议案》已经公司第三届董事 会第五次会议审议通过，关联董事回避表决，表决程序符合有关规定。本次交易 系公司在日常经营业务中发生的交易，符合公司正常生产经营的需要，为正常的 商业安排；交易价格严格遵循公开、公平、公正及市场化定价原则，不存在损害 公司及股东特别是中小股东利益的情形。本次交易对公司的财务状况、经营成果 不产生任何不利影响，公司的主要业务也不会因本次交易而对关联方形成依赖。 因此，我们同意本次交易及其项下的预计交易金额额度。 无锡药明康德新药开发股份有限公司独立董事 关于公司第三届董事会第五次会议审议的相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《上海证券交易所股票上市规则》《无锡药明康德新药开发股份有限 公司章程》等有关规定，作为无锡药明康德新药开发股份有限公司（以下简称"公 司"）独立董事，基于独立、客观判断的原则，我们对公司第三届董事会第五次 会议审议的相关事项发表独立意见如下： （以下无正文，为签署页） ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-071 无锡药明康德新药开发股份有限公司 关于与关联方签署框架协议暨日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次交易系无锡药明康德新药开发股份有限公司（以下简称"公司"）及 公司合并报表范围内的下属子企业（以下合称"本集团"）在日常经营业务中发 生的交易，符合本集团正常生产经营的需要，均为正常的商业安排。本次交易按 一般商务条款订立，关联交易价格严格遵循公开、公平、公正及市场化定价原则， 并通过签署书面合同的方式确定双方的权利义务关系，不存在损害公司及股东特 别是中小股东利益的情形。公司的主要业务不会因本次交易而对关联方形成依赖， 不会影响公司的独立性。 本次交易无需提交公司股东大会审议。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2023 年 11 月 3 日，经公司同日召开的第三届董事会第五次会议审议批准，公 司与 WuXi XDC Cayman Inc.（以下简称"XDC 开曼"）签署《有效载 ...

我们认为本次交易系公司在日常经营业务中发生的交易，符合公司正常生产 经营的需要，为正常的商业安排；交易价格严格遵循公开、公平、公正及市场化 定价原则，不存在损害公司及股东特别是中小股东利益的情形。本次交易对公司 的财务状况、经营成果不产生任何不利影响，公司的主要业务也不会因本次交易 而对关联方形成依赖。因此，我们同意本次交易及其项下的预计交易金额额度， 并同意将该议案提交公司第三届董事会第五次会议审议。 无锡药明康德新药开发股份有限公司 （以下无正文，为签署页） 第三届董事会第五次会议相关事项的独立董事事前认可意见 我们收到无锡药明康德新药开发股份有限公司（以下简称"公司"）将于 2023 年 11 月 3 日以通讯方式召开公司第三届董事会第五次会议的通知，对本次 会议拟审议的《关于与关联方签署框架协议暨日常关联交易的议案》进行了认真 的审核。 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-070 无锡药明康德新药开发股份有限公司 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司监事会认为，《关于与关联方签署框架协议暨日常关联交易的议案》已 经公司第三届董事会第五次会议审议通过，关联董事已在审议该议案的董事会上 回避表决，表决程序符合有关法律法规及《公司章程》的规定。本次交易系公司 在日常经营业务中发生的交易，符合公司正常生产经营的需要，为正常的商业安 排；交易价格严格遵循公开、公平、公正及市场化定价原则，不存在损害公司及 股东特别是中小股东利益的情形。公司的主要业务不会因本次交易而对关联方形 成依赖。因此，同意本次交易及其项下的预计交易金额额度，并同意公司签署《有 效载荷连接子主服务框架协议》。 具体内容详见本公司同日于上海证券交易所网站（www.sse.com.cn）及指定 媒体披露的《关于与关联方签署框架协议暨日常关联交易的公告》。 1 表决结果：3 票赞成，0 票反对，0 票弃权。 特此公告。 无锡药明 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2023年11月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 402,543,650 | RMB | | 1 | RMB | | 402,543,650 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 402,543,650 | RMB | | 1 | RMB | | 402,543,650 | | 2. 股份分類 | 普通 ...

Financial Performance - The company's revenue for Q3 2023 reached RMB 10.67 billion, a year-on-year increase of 0.30%[8] - Net profit attributable to shareholders was RMB 2.76 billion, reflecting a year-on-year increase of 0.77%[8] - The net profit excluding non-recurring gains and losses was RMB 2.95 billion, up 23.76% year-on-year[8] - The diluted earnings per share for Q3 2023 was RMB 0.94, a 16.05% increase year-on-year[9] - The company achieved a revenue of RMB 2,954,132.61 million in the first three quarters of 2023, representing a year-on-year growth of 4.0%[13] - Total operating revenue for the first three quarters of 2023 reached ¥29,541,326,133.58, an increase from ¥28,394,561,790.41 in the same period of 2022, representing a growth of approximately 4%[27] - Net profit for the first three quarters of 2023 was ¥8,148,647,084.33, up from ¥7,446,617,606.20 in 2022, reflecting an increase of approximately 9.4%[27] - Basic earnings per share for the first three quarters of 2023 was ¥2.75, compared to ¥2.52 in the previous year, representing an increase of about 9.1%[28] - The company reported a net profit of CNY 2,791,751,000 in Q3 2023, slightly up from CNY 2,770,959,000 in Q3 2022, indicating consistent profitability[34] Revenue Breakdown - Revenue from U.S. clients was RMB 19.4 billion, a 36% increase year-on-year after excluding specific commercial production projects[12] - Revenue from the top 20 global pharmaceutical companies reached RMB 11.82 billion, showing a strong growth of 43% year-on-year after excluding specific commercial production projects[12] - The chemical business generated revenue of RMB 212.4 billion, a 2.0% increase year-on-year, with a strong growth of 31.0% when excluding specific commercial production projects[14] - The testing business reported revenue of RMB 48.5 billion, up 16.2% year-on-year, with a gross margin of 38.6%, an increase of 1.8 percentage points[15] - The biology business achieved revenue of RMB 18.9 billion, a 6.5% increase year-on-year, with a gross margin of 42.8%[16] - The TIDES business revenue reached RMB 20.7 billion, reflecting a robust growth of 38.1% year-on-year, with a significant order backlog increase of 245%[14] - The cell and gene therapy CTDMO business generated revenue of RMB 10.3 billion, growing by 11.6%, although it reported a negative gross margin of -6.1%[16] - The domestic new drug development services segment saw a revenue decline of 26.9% to RMB 4.9 billion, despite an improved gross margin of 31.6%[17] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period increased by 33.82% to RMB 10.32 billion[11] - The company's total assets as of the end of Q3 2023 were RMB 71.76 billion, a 10.93% increase from the end of the previous year[9] - The company's total cash and cash equivalents at the end of Q3 2023 stood at CNY 9,446,351,731, an increase from CNY 9,213,956,461 at the end of Q3 2022[31] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 10,316,787,860, significantly higher than CNY 7,709,650,548 in the same period of 2022, indicating improved operational efficiency[30] - The company’s total liabilities increased to ¥19,770,878,845.60 from ¥17,763,654,011.21, indicating a rise of about 11.3%[27] - The company’s total liabilities as of September 30, 2023, were reported to be lower than the previous year, indicating improved financial health[36] Future Outlook - In Q4 2023, the company expects revenue from non-specific commercial production projects to exceed RMB 10 billion for the first time, with a projected growth of 29-34% excluding specific projects[18] - The overall revenue for 2023 is anticipated to surpass RMB 40 billion, with a growth of 25-26% when excluding specific commercial production projects[18] - The adjusted non-IFRS gross margin for 2023 is raised to approximately 41.7-42.1%, an increase of about 0.5 percentage points[18] - The adjusted net profit attributable to the parent company is expected to exceed RMB 10 billion for the first time in 2023[18] - Free cash flow under IFRS for 2023 is projected to be between RMB 4.5-5 billion, over 17 times that of the same period last year[18] - The company has adjusted its revenue growth forecast for 2023 from 5-7% to 2-3% due to lower-than-expected demand in early-stage drug development[18] Shareholder Information - The total number of ordinary shareholders as of September 30, 2023, is 202,845[20] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 402,500,362 shares, representing 13.56% of the total[20] - The company’s total equity attributable to shareholders increased to CNY 51,586,653 thousand from CNY 46,589,953 thousand, reflecting a growth of about 10.5%[38] Research and Development - The company added 926 new molecules to its D&M pipeline, surpassing a total of 3,000 molecules, including 58 commercial projects and 61 clinical phase III projects[14] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth, although specific figures were not disclosed in the report[32]

Financial Performance - The company's operating revenue for Q3 2023 was approximately RMB 10.67 billion, representing a year-on-year increase of 0.30%[7] - The net profit attributable to shareholders for the same period was approximately RMB 2.76 billion, reflecting a year-on-year increase of 0.77%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 2.95 billion, with a significant year-on-year increase of 23.76%[7] - The cash flow from operating activities for the year-to-date period reached approximately RMB 10.32 billion, showing a substantial increase of 33.82% compared to the previous year[7] - The basic earnings per share for Q3 2023 was RMB 0.94, an increase of 1.08% year-on-year[7] - The diluted earnings per share for the same period was also RMB 0.94, reflecting a significant increase of 16.05% year-on-year[7] - The company achieved operating revenue of RMB 29.54 billion in the first three quarters of 2023, representing a year-on-year growth of 4.0%[12] - Total operating revenue for the first three quarters of 2023 reached RMB 29.54 billion, an increase of 4.03% compared to RMB 28.39 billion in the same period of 2022[27] - Net profit for the first three quarters of 2023 was RMB 8.15 billion, representing a growth of 9.43% from RMB 7.45 billion in the same period of 2022[28] - The company reported a total profit of RMB 9.78 billion, an increase of 10.98% compared to RMB 8.82 billion in the same period of 2022[27] - The total comprehensive income for the first three quarters was RMB 7.60 billion, an increase of 13.63% from RMB 6.69 billion in the same period of 2022[30] Revenue Sources - Revenue from American clients reached RMB 19.4 billion, with a year-on-year growth of 36% after excluding COVID-19 commercialization projects[10] - Revenue from the top 20 global pharmaceutical companies reached RMB 11.82 billion, with a strong year-on-year growth of 43% after excluding COVID-19 projects[10] - The company’s revenue from existing clients accounted for nearly 99%, totaling RMB 29.12 billion, with a year-on-year growth of 26% after excluding COVID-19 projects[10] - Revenue from the testing business was RMB 4.85 billion, reflecting a year-on-year increase of 16.2%[14] - WuXi Biology achieved revenue of RMB 1.89 billion, a year-on-year increase of 6.5%, with an adjusted gross margin of 42.8%, up 1.6 percentage points year-on-year[15] - WuXi ATU's cell and gene therapy CTDMO business generated revenue of RMB 1.03 billion, an increase of 11.6% year-on-year, with an adjusted gross margin of -6.1%[16] - The new molecular biology-related revenue in the biology segment grew strongly by 35% year-on-year, contributing 25.9% to the overall biology business revenue[15] Cash Flow and Assets - The cash flow from operating activities increased by 33.82% year-on-year, attributed to stable revenue collection and optimized working capital management[9] - Cash and cash equivalents reached ¥9,448,561,845.32, up from ¥7,985,741,393.85, reflecting a growth of about 18.3%[24] - Total current assets amounted to ¥29,777,189,611.66, an increase of approximately 24.0% from ¥23,997,226,540.21 on December 31, 2022[24] - Total assets as of September 30, 2023, were ¥71,759,281,237.93, compared to ¥64,690,326,746.96 at the end of 2022, indicating a growth of around 10.0%[26] - The company’s cash balance at the end of the third quarter of 2023 was ¥9,446,351,731.41, compared to ¥9,213,956,461.06 at the end of the third quarter of 2022[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 202,845[19] - The company paid dividends amounting to RMB 2,649,084 thousand in 2023, which is an increase of 73.4% compared to RMB 1,529,442 thousand in 2022[39] Future Outlook - The company expects significant growth in TIDES business revenue in Q4 2023, projected to exceed 60% for the full year[13] - The company anticipates that revenue from non-COVID commercial production projects in Q4 2023 will exceed RMB 10 billion for the first time[18] - Excluding COVID-related projects, the company expects Q4 revenue growth of 29-34% and a full-year revenue increase of 25-26%[18] - The adjusted gross margin for the full year 2023 is projected to be between 41.7% and 42.1%, with net profit expected to exceed RMB 10 billion for the first time[18] - The company has adjusted its 2023 revenue growth forecast from 5-7% to 2-3% due to lower-than-expected demand in early drug development stages[18] Employee Information - The company employed a total of 41,148 staff, with 12,877 holding a master's degree or above, and 1,400 holding a doctoral degree or equivalent[5] - The company continues to focus on talent retention through recruitment, training, promotion, and incentives to maintain high service standards and industry leadership[5]

证券代码：603259 证券简称：药明康德 公告编号：临 2023-065 无锡药明康德新药开发股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2023 年 10 月 16 日及 2023 年 10 月 29 日向本公司全体董事发出会议通知及会议 材料。经全体董事一致认可，以现场结合通讯表决方式于 2023 年 10 月 30 日按 期召开第三届董事会第四次会议。本次董事会会议应出席董事 12 人，实际出席 董事 12 人。会议由董事长 Ge Li（李革）主持。本次董事会符合《中华人民共和 国公司法》和《无锡药明康德新药开发股份有限公司章程》关于召开董事会会议 的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年第三季度报告的议案》 同意《无锡药明康德新药开发股份有限公司 2023 年第三季度报告》的相关 内容。 具体内容详见本公司同日于上海证券交易所网站（www.sse ...